Replimune Group (NASDAQ:REPL) Shares Gap Up – What’s Next?

Replimune Group, Inc. (NASDAQ:REPL)’s share price gapped up before the market opened on Tuesday . The stock had previously closed at $10.14, but opened at $12.60. Replimune Group shares last traded at $12.39, with a volume of 337,188 shares.

Wall Street Analysts Forecast Growth

REPL has been the topic of a number of analyst reports. JPMorgan Chase & Co. lifted their price target on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. BMO Capital Markets boosted their target price on shares of Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Friday, November 22nd. HC Wainwright restated a “buy” rating and issued a $17.00 price target on shares of Replimune Group in a report on Friday, November 22nd. Finally, Jefferies Financial Group increased their target price on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $17.29.

Replimune Group Price Performance

The stock has a 50 day moving average of $12.16 and a 200-day moving average of $11.24. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The company has a market cap of $809.82 million, a PE ratio of -3.83 and a beta of 1.28.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. Equities analysts predict that Replimune Group, Inc. will post -2.91 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Sushil Patel sold 10,000 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the sale, the chief executive officer now directly owns 202,014 shares of the company’s stock, valued at $2,509,013.88. This represents a 4.72 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the sale, the insider now owns 109,885 shares in the company, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.80% of the stock is owned by insiders.

Institutional Trading of Replimune Group

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Point72 DIFC Ltd purchased a new position in Replimune Group in the 2nd quarter valued at about $57,000. Erste Asset Management GmbH acquired a new stake in shares of Replimune Group in the third quarter worth approximately $133,000. China Universal Asset Management Co. Ltd. increased its position in shares of Replimune Group by 82.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock worth $144,000 after purchasing an additional 5,926 shares in the last quarter. BNP Paribas Financial Markets raised its stake in Replimune Group by 81.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company’s stock valued at $165,000 after purchasing an additional 6,748 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new position in Replimune Group in the 3rd quarter valued at $222,000. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.